

## **Strides gets US FDA nod to market skin disease drug**

Strides Arcolab has received regulatory approval to market a skin disease drug in the US. The US Food and Drug Administration (FDA) has allowed the company to sell Methoxsalen capsules of 10 mg strength, Bangalore-based Strides Arcolab said in a statement. The US market for generic Methoxsalen capsules is pegged at about \$13.6 million, with no generic player, the company said, citing IMS data. "The product will be manufactured at the company's Food and Drug Administration-approved oral dosage facility in Bangalore and marketed directly by Strides in the US," the company said.

*Regulatory.*